The Department of Health and Human Services Food and Drug Administration awarded a sole source, firm-fixed price purchase order to Oxford Nanopore Technologies Inc. in the amount of $100,060.00 for the acquisition of two GridION X5 devices. This award was made without a set-aside designation and has a completion date of January 21, 2020. The GridION X5 is a nanopore-based sequencing system used for genomic analysis applications such as infectious disease tracking and agricultural genomics. Oxford Nanopore Technologies Inc. is a subsidiary of Oxford Nanopore Technologies PLC, a provider of next-generation sequencing equipment, consumables, and services to various federal agencies including the NIH, CDC, USDA, and DOD. The FDA determined that the GridION X5 was the only system that met their specific requirements for a deployable long-read sequencer capable of fully automated, real-time nucleic acid sequencing.